Ztalmy is a medicine used to treat epileptic seizures in children from 2 to 17 years of age who have a condition known as cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. These patients can continue taking Ztalmy when they become adults if a clear benefit has been observed. The medicine is used in combination with other anti-epileptic medicines. CDKL5 deficiency disorder is rare, and Ztalmy was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 13 November 2019. Further information on the orphan designation can be found on the EMA [website](/en/medicines/human/orphan-designations/eu-3-19-2224). Ztalmy contains the active substance ganaxolone.
Therapeutic Indication
### Therapeutic indication Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.
Therapeutic Area (MeSH)
ATC Code
N03AX
ATC Item
其它抗癫痫药
Pharmacotherapeutic Group
Other antiepileptics
Active Substance (Summary)
INN / Common Names
EMA Name
Ztalmy
Medicine Name
Ztalmy
Aliases
N/A